Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema
Abstract This prospective, open-label, single-arm, non-randomized clinical trial, assessed the efficacy of a 2-year treat-and-extend (T&E) regimen involving intravitreal aflibercept injection (IAI), with the longest treatment interval set to 16 weeks, and adjunct focal/grid laser in diabetic mac...
Guardado en:
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/f5ae93ccb074428ea8a2b9a23ae71181 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:f5ae93ccb074428ea8a2b9a23ae71181 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:f5ae93ccb074428ea8a2b9a23ae711812021-12-02T13:33:51ZOutcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema10.1038/s41598-021-83811-y2045-2322https://doaj.org/article/f5ae93ccb074428ea8a2b9a23ae711812021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-83811-yhttps://doaj.org/toc/2045-2322Abstract This prospective, open-label, single-arm, non-randomized clinical trial, assessed the efficacy of a 2-year treat-and-extend (T&E) regimen involving intravitreal aflibercept injection (IAI), with the longest treatment interval set to 16 weeks, and adjunct focal/grid laser in diabetic macula edema (DME) patients. We examined 40 eyes (40 adults) with fovea-involving DME from 8 Japanese centers between April 2015 and February 2017. Participants received IAI with an induction period featuring monthly injections and a subsequent T&E period featuring 8–16-week injection interval, adjusted based on optical coherence tomography findings. The primary endpoints were mean changes in the best-corrected visual acuity (BCVA) and central subfield macular thickness (CST) from baseline. Thirty patients (75%) completed the 2-year follow-up. The mean BCVA and CST changed from 60.5 ± 15.6 letters and 499.2 ± 105.6 µm at baseline to 66.6 ± 17.1 letters (P = 0.217) and 315.2 ± 79.0 µm (P < 0.001), respectively, after 2 years. The treatment interval was extended to 12 and 16 weeks in 6.7% and 66.7% of patients, respectively, at the end of 2 years. The T&E aflibercept regimen with the longest treatment interval set to 16 weeks, with adjunct focal/grid laser may be a rational 2-year treatment strategy for DME.Takao HiranoYuichi ToriyamaYoshihiro TakamuraMasahiko SugimotoTaiji NagaokaYoshimi SugiuraFumiki OkamotoMichiyuki SaitoKousuke NodaShigeo YoshidaAkihiro IshibazawaOsamu SawadaToshinori MurataNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Takao Hirano Yuichi Toriyama Yoshihiro Takamura Masahiko Sugimoto Taiji Nagaoka Yoshimi Sugiura Fumiki Okamoto Michiyuki Saito Kousuke Noda Shigeo Yoshida Akihiro Ishibazawa Osamu Sawada Toshinori Murata Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema |
| description |
Abstract This prospective, open-label, single-arm, non-randomized clinical trial, assessed the efficacy of a 2-year treat-and-extend (T&E) regimen involving intravitreal aflibercept injection (IAI), with the longest treatment interval set to 16 weeks, and adjunct focal/grid laser in diabetic macula edema (DME) patients. We examined 40 eyes (40 adults) with fovea-involving DME from 8 Japanese centers between April 2015 and February 2017. Participants received IAI with an induction period featuring monthly injections and a subsequent T&E period featuring 8–16-week injection interval, adjusted based on optical coherence tomography findings. The primary endpoints were mean changes in the best-corrected visual acuity (BCVA) and central subfield macular thickness (CST) from baseline. Thirty patients (75%) completed the 2-year follow-up. The mean BCVA and CST changed from 60.5 ± 15.6 letters and 499.2 ± 105.6 µm at baseline to 66.6 ± 17.1 letters (P = 0.217) and 315.2 ± 79.0 µm (P < 0.001), respectively, after 2 years. The treatment interval was extended to 12 and 16 weeks in 6.7% and 66.7% of patients, respectively, at the end of 2 years. The T&E aflibercept regimen with the longest treatment interval set to 16 weeks, with adjunct focal/grid laser may be a rational 2-year treatment strategy for DME. |
| format |
article |
| author |
Takao Hirano Yuichi Toriyama Yoshihiro Takamura Masahiko Sugimoto Taiji Nagaoka Yoshimi Sugiura Fumiki Okamoto Michiyuki Saito Kousuke Noda Shigeo Yoshida Akihiro Ishibazawa Osamu Sawada Toshinori Murata |
| author_facet |
Takao Hirano Yuichi Toriyama Yoshihiro Takamura Masahiko Sugimoto Taiji Nagaoka Yoshimi Sugiura Fumiki Okamoto Michiyuki Saito Kousuke Noda Shigeo Yoshida Akihiro Ishibazawa Osamu Sawada Toshinori Murata |
| author_sort |
Takao Hirano |
| title |
Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema |
| title_short |
Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema |
| title_full |
Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema |
| title_fullStr |
Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema |
| title_full_unstemmed |
Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema |
| title_sort |
outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/f5ae93ccb074428ea8a2b9a23ae71181 |
| work_keys_str_mv |
AT takaohirano outcomesofa2yeartreatandextendregimenwithafliberceptfordiabeticmacularedema AT yuichitoriyama outcomesofa2yeartreatandextendregimenwithafliberceptfordiabeticmacularedema AT yoshihirotakamura outcomesofa2yeartreatandextendregimenwithafliberceptfordiabeticmacularedema AT masahikosugimoto outcomesofa2yeartreatandextendregimenwithafliberceptfordiabeticmacularedema AT taijinagaoka outcomesofa2yeartreatandextendregimenwithafliberceptfordiabeticmacularedema AT yoshimisugiura outcomesofa2yeartreatandextendregimenwithafliberceptfordiabeticmacularedema AT fumikiokamoto outcomesofa2yeartreatandextendregimenwithafliberceptfordiabeticmacularedema AT michiyukisaito outcomesofa2yeartreatandextendregimenwithafliberceptfordiabeticmacularedema AT kousukenoda outcomesofa2yeartreatandextendregimenwithafliberceptfordiabeticmacularedema AT shigeoyoshida outcomesofa2yeartreatandextendregimenwithafliberceptfordiabeticmacularedema AT akihiroishibazawa outcomesofa2yeartreatandextendregimenwithafliberceptfordiabeticmacularedema AT osamusawada outcomesofa2yeartreatandextendregimenwithafliberceptfordiabeticmacularedema AT toshinorimurata outcomesofa2yeartreatandextendregimenwithafliberceptfordiabeticmacularedema |
| _version_ |
1718392832179306496 |